Investors

Company Profile

Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.

Financial Reports

Sorry, there are no financial reports available yet.

Investor presentations

Wedbush Presentation August 2019 in NYC

KOL Event in NYC July 2019

Jefferies Healthcare Conference Presentation – June 2019

ObsEva Short Report 2018

1 2 3

Press Releases

ObsEva Receives Clearance from US FDA to Initiate Phase 2b Study EDELWEISS with OBE2109, a Potentially Best-in-Class Oral GnRH Antagonist, for the Treatment of Endometriosis

press release

July 6, 2016

Geneva, Switzerland, 06 July, 2016 – ObsEva, a Swiss biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics, today announced that its…

Read more

ObsEva to Webcast Presentation at 15th Annual Needham Healthcare Conference

press release

April 5, 2016

Geneva, Switzerland, 05 April, 2016 – ObsEva, a Swiss biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics, today announced that Ernest Loumaye,…

Read more

ObsEva Strengthens Board with Appointment of Biotechnology Veteran Dr. Frank Verwiel

press release

March 24, 2016

Geneva, Switzerland, 24 March 2016 – ObsEva, a Swiss biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics, today announced…

Read more
1 79 80 81 82 83 86

General Meetings

ObsEva Annual General Meeting 2021

May 28, 2021

Read more

ObsEva Annual General Meeting 2020

June 9, 2020

Read more
1 2 3 4

Upcoming Events

Half Year 2024 Financial Results: 30 September 2024

Event


    Read more

    Annual General Meeting: Thursday 27 June, 2024

    Event


      Read more

      Obseva 2023 Swiss Annual Report: 30 April, 2024

      Event


        Read more
         

        Contacts

        ObsEva Switzerland Office

        Chemin des Aulx,12

        1228, Plan-Les-Ouates, Geneva, Switzerland

        +41 (0)22 552 3840


        contact@obseva.ch

        Investor relations


        IR@obseva.ch

        CEO Office

        +41 (0)22 552 1550


        contact@obseva.ch

         

        Sign up for news

         
         

          * Type:


          InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












          Read our privacy policy here.


           

          Are you sure you want to leave ObsEva.com?

          We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

          Continue to link

          Disclaimer

          Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

          Continue

          Disclaimer

          Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

          Continue